Drug intelligence / Profile preview

C-Sept PRO

Development stage: Unknown
Lead developer: Kosmos
Modality: Small Molecules
Administration: Topical

Overview

C-Sept PRO is a professional-grade cutaneous antiseptic solution developed by Cana Laboratories, a subsidiary of Cosmos Health. It is formulated as a combination of 2% w/v chlorhexidine digluconate and 76% v/v isopropyl alcohol. The solution is designed for fast-acting, broad-spectrum antimicrobial antisepsis of clean hands and intact skin, offering rapid initial action from the alcohol component and prolonged antimicrobial activity from chlorhexidine. In clinical and hospital settings, C-Sept PRO is indicated for surgical and daily hand disinfection, pre-operative skin preparation, skin preparation prior to injections and venipunctures, and local skin disinfection before central or peripheral vascular catheterization.

Brand names: C-Sept PRO
Other names: C-Sept Pro 2%

Beyond the preview

Go deeper on C-Sept PRO.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C-Sept PRO.

Explore the full profile